Paper39115191
Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer.
Werner B and 9 others. Mol Oncol, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer. Papers, record 39115191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39115191
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ovarian Neoplasms | Major topic |
| Ascites | Major topic |
| Cell-Free Nucleic Acids | Major topic |
| Humans | |
| Female | |
| Mutation | |
| Middle Aged | |
| DNA Copy Number Variations | |
| Aged | |
| Loss of Heterozygosity | |
| High-Throughput Nucleotide Sequencing | |
| Biomarkers, Tumor |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| NIH | PubMed | |||
| Australian Academy of Science | PubMed |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31344859 | Rare Distant Metastatic Disease of Ovarian and Peritoneal Carcinomatosis: A Review of the Literature. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31344859 | PubMed |
| 2 | 33302872 | PyClone-VI: scalable inference of clonal population structures using whole genome data. | BMC Bioinformatics | 2020 | https://conductscience.org/library/papers/33302872 | PubMed |
| 3 | 15374957 | Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. | Cancer Res | 2004 | https://conductscience.org/library/papers/15374957 | PubMed |
| 4 | 37932736 | Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37932736 | PubMed |
| 5 | 33233347 | Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33233347 | PubMed |
| 6 | 37597580 | Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2023 | https://conductscience.org/library/papers/37597580 | PubMed |
| 7 | 30380390 | Application of Cell-free DNA Analysis to Cancer Treatment. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30380390 | PubMed |
| 8 | 38097143 | The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models. | Biochim Biophys Acta Rev Cancer | 2024 | https://conductscience.org/library/papers/38097143 | PubMed |
| 9 | 29592813 | Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. | Genome Med | 2018 | https://conductscience.org/library/papers/29592813 | PubMed |
| 10 | 37700064 | The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37700064 | PubMed |
| 11 | 33506580 | Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer. | J Obstet Gynaecol Res | 2021 | https://conductscience.org/library/papers/33506580 | PubMed |
| 12 | 34069200 | Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34069200 | PubMed |
| 13 | 28916367 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2017 | https://conductscience.org/library/papers/28916367 | PubMed |
| 14 | 34454680 | Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. | Gynecol Oncol | 2021 | https://conductscience.org/library/papers/34454680 | PubMed |
| 15 | 20818904 | Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20818904 | PubMed |
| 16 | 32496546 | SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update). | Nucleic Acids Res | 2020 | https://conductscience.org/library/papers/32496546 | PubMed |
| 17 | 21720365 | Integrated genomic analyses of ovarian carcinoma. | Nature | 2011 | https://conductscience.org/library/papers/21720365 | PubMed |
| 18 | 36849657 | Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. | Nat Genet | 2023 | https://conductscience.org/library/papers/36849657 | PubMed |
| 19 | 26017449 | Whole-genome characterization of chemoresistant ovarian cancer. | Nature | 2015 | https://conductscience.org/library/papers/26017449 | PubMed |
| 20 | 31722153 | Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31722153 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42786656 | Circulating tumour cells for guiding antibody‒drug conjugate therapy: Role of artificial intelligence. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42786656 | PubMed |
| 42366335 | Proteomic analysis of malignant ascites and its impact on ovarian cancer spheroids. | Clin Proteomics | 2026 | https://conductscience.org/library/papers/42366335 | PubMed |
| 41413429 | Genomic alterations linked to recurrence risk in high-grade serous ovarian cancer revealed by deep targeted sequencing. | Sci Rep | 2025 | https://conductscience.org/library/papers/41413429 | PubMed |
| 41363274 | Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma. | Int J Cancer | 2026 | https://conductscience.org/library/papers/41363274 | PubMed |
| 41244344 | Development and validation of a computational tool to predict treatment outcomes in cells from high-grade serous ovarian cancer patients. | Bioeng Transl Med | 2025 | https://conductscience.org/library/papers/41244344 | PubMed |
| 41088281 | Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41088281 | PubMed |
| 40278372 | Cell-Free DNA (cfDNA) Regulates Metabolic Remodeling in the ES-2 Ovarian Carcinoma Cell Line, Influencing Cell Proliferation, Quiescence, and Chemoresistance in a Cell-of-Origin-Specific Manner. | Metabolites | 2025 | https://conductscience.org/library/papers/40278372 | PubMed |
| 40051502 | Immunomagnetic enrichment coupled to PAX8/TP53 molecular pathology approach increases sensitivity in the detection of ovarian cancer cells in ascites. | Front Mol Biosci | 2025 | https://conductscience.org/library/papers/40051502 | PubMed |
| 39591206 | Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer. | Cancer Res Commun | 2024 | https://conductscience.org/library/papers/39591206 | PubMed |
| 39221267 | Beyond 2D cell cultures: how 3D models are changing the in vitro study of ovarian cancer and how to make the most of them. | PeerJ | 2024 | https://conductscience.org/library/papers/39221267 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| BRCA2 | 675 | PubTator's text mining | https://conductscience.org/library/genes/675 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39115191
GET https://conductscience.org/api/papers/v1/39115191/references?page=2